This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stomp the S&P With 5 Hated Stocks Ready to Pop

Johnson & Johnson

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

It may seem surprising that a staid blue-chip name such as Johnson & Johnson (JNJ - Get Report) could top off our list of hated stocks, but investors are piling in against this stock right now. As I write, JNJ's short interest ratio comes in at 10.7, which indicates that it would take more than two full weeks of buying pressure for shorts to exit their bets under current volume levels. That makes this $215 billion health care company a prime candidate for a short squeeze this year.

>>5 Dow Dogs That Could Stomp the Market in 2013

Johnson & Johnson may be best known for its prolific line of consumer medical products, such as Band-Aid bandages and baby shampoo, but its business also includes more complex pharmaceuticals and medical devices as well. In fact, that's a big part of JNJ's big short interest right now, with investors anxious about the pharma industry as a whole thanks to looming patent losses.

But JNJ is one of the best-positioned pharma firms, so its biggest source of profitability isn't in much peril. Meanwhile, the other business units provide stellar diversification in what's already a defensive industry.

Financially, Johnson & Johnson is in stellar shape. The firm carries a $21 billion cash position on its balance sheet, with around $5 billion of that sticking around net of total debt. That gives JNJ plenty of financial security in 2013, and it helps to secure the firm's 3.1% dividend payout right now.

Expect shares' 12.5% rally year-to-date to carry on to the second quarter.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ASML $86.03 -0.38%
FAST $43.84 0.41%
INFY $16.33 -1.30%
JNJ $101.72 -0.27%
MTB $106.73 0.78%


Chart of I:DJI
DOW 16,005.41 -21.64 -0.14%
S&P 500 1,851.28 -2.16 -0.12%
NASDAQ 4,284.17 +0.4170 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs